Labcorp has begun rolling out a new blood test that aims to predict the risk of a pregnant person developing preeclampsia, with screening results available as early as the first trimester. The test is ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min As the number of Americans at ...

Add Yahoo as a preferred source to see more of our stories on Google. The new test measures the risk of preeclampsia with up to 90% sensitivity and 90% specificity, according to Labcorp. Photo by ...

Labcorp plans to offer Roche’s recently FDA-cleared blood test to assess early signs of Alzheimer’s disease and other causes of cognitive decline for patients 55 years and older. The blood test, which ...

(RTTNews) - Labcorp (LH) Wednesday has introduced the pTau-217/Beta Amyloid 42 Ratio test, a blood-based biomarker designed to aid in Alzheimer's diagnosis. Offering accuracy comparable to PET imaging ...

Labcorp Holdings, Inc. LH has announced the nationwide availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio — the first FDA-cleared blood-based in-vitro diagnostic (IVD) test to assist in ...

Labcorp, one of the country’s largest providers of diagnostic medical testing services, announced today that it will offer the only blood test cleared by the U.S. Food and Drug Administration to aid ...

Preeclampsia can be a life-threatening complication of pregnancy, but a new blood test can help predict a woman's risk for the condition while she is in her first trimester, the test's maker said ...

BURLINGTON, N.C., Feb. 11, 2026 /PRNewswire/ -- Labcorp (LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide availability of the Elecsys® pTau-181 ...